Polyrizon Says It Completed Contracting With All Five U.S. Clinical Sites For First-In-Human Study Of NASARIX Allergy Blocker, Planned To Enroll Up To 120 Patients
Share
Why It Matters
Polyrizon finished signing up all five hospitals to test a new allergy medicine on people for the first time. This is a regular step forward in medicine-making, so watch if the company stays on schedule with its testing plans.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.